Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CO16, A8501015 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This protocol allows patients who completed Coley oncology studies using PF-3512676 (CPG 7909) Injection to continue receiving the treatment until disease progression.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Patients will be treated with the same dosing regimen and schedule of PF-3512676 Injection with which they were treated at the end of the previous PF-3512676 Injection trial. Any proposed changes to their schedule/regimen will be at the discretion of the treating physician, following consultation with Coley. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-3512676 | Drug | PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg. |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events and DLTs will be evaluated by the Investigator and summarized. | indeterminate |
| Measure | Description | Time Frame |
|---|---|---|
| No formal statistical analysis of this study will be conducted. All clinical data may be summarized and included in data listings. | indeterminate |
Not provided
Inclusion Criteria:
Immediate (within 4 weeks) prior completion of a clinical trial of PF-3512676 Injection alone or in combination with other anti-neoplastic treatment for malignancy.
Exclusion Criteria:
The patient has received any anti-neoplastic therapy since completing a prior trial with PF-3512676 Injection, or has participated in another clinical trial following participation in a trial with PF-3512676 Injection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Berkely | California | 94704 | United States | ||
| Pfizer Investigational Site |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Gilroy |
| California |
| 95020 |
| United States |
| Pfizer Investigational Site | Hollister | California | 95023 | United States |
| Pfizer Investigational Site | Los Angeles | California | 90057 | United States |
| Pfizer Investigational Site | Los Angeles | California | 91342 | United States |
| Pfizer Investigational Site | Palm Springs | California | 92262 | United States |
| Pfizer Investigational Site | Stanford | California | 94305 | United States |
| Pfizer Investigational Site | New Haven | Connecticut | 06504 | United States |
| Pfizer Investigational Site | Bonita Springs | Florida | 34135 | United States |
| Pfizer Investigational Site | Bradenton | Florida | 34209 | United States |
| Pfizer Investigational Site | Cape Coral | Florida | 33990 | United States |
| Pfizer Investigational Site | Fort Myers | Florida | 33901 | United States |
| Pfizer Investigational Site | Fort Myers | Florida | United States |
| Pfizer Investigational Site | Naples | Florida | 34102 | United States |
| Pfizer Investigational Site | Plantation | Florida | 33324 | United States |
| Pfizer Investigational Site | Port Charlotte | Florida | 33980 | United States |
| Pfizer Investigational Site | Sarasota | Florida | 34232 | United States |
| Pfizer Investigational Site | Venice | Florida | 34285 | United States |
| Pfizer Investigational Site | Venice | Florida | 34292 | United States |
| Pfizer Investigational Site | Chicago | Illinois | 60611-3124 | United States |
| Pfizer Investigational Site | Chicago | Illinois | 60611 | United States |
| Pfizer Investigational Site | Vincennes | Indiana | 47591 | United States |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | United States |
| Pfizer Investigational Site | Olive Branch | Mississippi | 38654 | United States |
| Pfizer Investigational Site | Oxford | Mississippi | 38655 | United States |
| Pfizer Investigational Site | Livingston | New Jersey | 07039 | United States |
| Pfizer Investigational Site | Asheville | North Carolina | 28801 | United States |
| Pfizer Investigational Site | Portland | Oregon | 97213 | United States |
| Pfizer Investigational Site | Collierville | Tennessee | 38107 | United States |
| Pfizer Investigational Site | Memphis | Tennessee | 38017 | United States |
| Pfizer Investigational Site | Memphis | Tennessee | 38104 | United States |
| Pfizer Investigational Site | Cologne | 50931 | Germany |
| ID | Term |
|---|---|
| D008545 | Melanoma |
| D001943 | Breast Neoplasms |
| D002292 | Carcinoma, Renal Cell |
| D016399 | Lymphoma, T-Cell |
| D002289 | Carcinoma, Non-Small-Cell Lung |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D001941 | Breast Diseases |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D008175 | Lung Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C483020 | ProMune |
Not provided
Not provided
Not provided